According to the US Department of Health and Human Services, approximately 42 million Americans suffer from arthritis. The joint care market is continually searching for the next great ingredient. Citrofen is here to fill that void. It is a proprietary blend from the bark of Phellodendron amurense and a patented (US Patent No. 6,184,246) formulation of Polymethoxylated flavones extracted from Citrus sinenis. A connection has been established between osteoarthritis and elevated C-Reactive Protein, a pro-inflammatory cytokine that increases during systemic inflammation.
Citrofen was clinically tested on subjects with osteoarthritis of the knee and the published results can be found in Nutrition Journal. By bringing CRP into normal range, inflammation decreased and symptoms of osteoarthritis diminished. The Lequesne Algofunctional Index (LAI) for joint pain and movement showed a significant decrease in scores between the Overweight Treatment Group versus the Overweight Placebo Group (p<0.0001). Furthermore, weight loss has proven to lessen the pain and severity of OA. The trial conducted on Citrofen showed a statistically significant weight loss in its overweight patients over an 8-week period (p<0.001). Ideal for weight management and increased joint mobility and comfort, Citrofen is the promising new product for the joint care category.
We're proud to announce that Citrofen is now produced in the US at a cGMP facility.
To read about the fascinating science on Citrofen, click on the link below.